問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Surgery

更新時間：2023-09-19

林明燦LIN, MING-TSAN
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

Recruiting Trial

1Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林明燦

List

5Cases

2020-10-26 - 2029-12-31

Phase III

Active
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients With Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC)

  • Condition/Disease

    esectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC)

  • Test Drug

    Durvalumab

Participate Sites
7Sites

Not yet recruiting5Sites

Recruiting2Sites

2017-08-01 - 2026-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2017-01-06 - 2022-01-05

Phase III

ONO-4538 Phase III Study A multicenter, double-blind, randomized study in patients with gastric cancer undergoing postoperative adjuvant chemotherapy

  • Condition/Disease

    Gastric Cancer

  • Test Drug

    Nivolumab

Participate Sites
10Sites

Terminated8Sites

白禮源
China Medical University Hospital-Taipei

未分科

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2018-04-19 - 2023-12-31

Phase III

A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)

  • Condition/Disease

    Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

  • Test Drug

    KEYTRUDA

Participate Sites
7Sites

Terminated7Sites

2007-11-05 - 2009-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB